LJI308

Research use only, not for human use.

LJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.

LJI308 is a RSK inhibitor. LJI308 overcomes chemoresistance by eliminating cancer stem cells. LJI308 targets the CSC population and repress TNBC growth and dissemination. LJI308 specifically targeted transformed cells as it had little effect on the non-tumorigenic parental HMECs. Targeting RSK using specific and potent inhibitors, such as LJI308, delivers the promise of inhibiting the growth of TNBC.

LJI308; LJI-308; LJI 308; NVP-LJI308; NVP-LJI-308

Angiogenesis

PDE

RSK1;RSK2;RSK3

Cancer

——

1627709-94-7

368.38

C21H18F2N2O2

98%

DMSO : ≥ 32 mg/mL 86.87 mM

Oc1c(F)cc(cc1F)-c1cnccc1-c1ccc(cc1)N1CCOCC1

2,6-Difluoro-4-[4-[4-(4-morpholinyl)phenyl]-3-pyridinyl]-phenol

(-20℃)

With Ice Pack

≥ 2 years